Hasselhorn H M, Nübling M, Tiller F W, Hofmann F
Arbeitsmedizin-Personalambulanz des Universitätsklinikums Freiburg.
Dtsch Med Wochenschr. 1997 Mar 7;122(10):281-6. doi: 10.1055/s-2008-1047609.
Nearly 50% of adults in Germany have no measurable antibody protection against diphtheria, even though most of them will have been vaccinated against it in their childhood. We investigated how vaccination should be performed in this situation to provide lasting protection.
100 adults (53 men, 47 women; mean age 27.7 [19-54] years) whose last diphtheria vaccination had been at least 10 years previously, were injected up to three times with customary commercial monovalent diphtheria vaccine for adults (5 IU toxoid/0.5 ml), at intervals of 4-8 weeks. Each time, before and 4-8 weeks after the latest injection, the antitoxin level was determined by cell-culture neutralization test.
Before the vaccination 30 of the 100 subjects had protection against diphtheria (antitoxin level > 0.1 IU/ml), 24 had "basic immunity" (0.01 to < 0.1 IU/ml), and 46 no measurable protection (< 0.01 IU/ml). After the first booster the protection threshold had not been reached in seven of the 100, all of them women. The main determinant for the pre- and post-vaccination antitoxin level was the interval since the last vaccination. In addition, women had significantly lower pre- and postvaccination levels than men. But after the second and third booster the antitoxin level of the seven women had risen to above the protection threshold, while the geometric mean of the whole collective had fallen, despite further boosters. It was 0.015 IU/ml before vaccination, 1.156 IU/ml after the first booster, 0.924 IU/ml after the second, and 0.952 after the third.
Those adults who were last vaccinated against diphtheria more than 20 years ago should have two booster shots, more than 8 weeks apart, so that the highest possible and most lasting antitoxin level can be achieved. Women in particular should have at least two booster shots, as their antitoxin response tends to be less than that of men.
在德国,近50%的成年人对白喉没有可测量的抗体保护,尽管他们中的大多数人在童年时期都接种过白喉疫苗。我们研究了在这种情况下应如何进行疫苗接种以提供持久保护。
100名成年人(53名男性,47名女性;平均年龄27.7[19 - 54]岁),他们上次接种白喉疫苗至少是在10年前,接受了高达三次的成人用常规商业单价白喉疫苗(5 IU类毒素/0.5 ml)注射,间隔4 - 8周。每次在最近一次注射前以及注射后4 - 8周,通过细胞培养中和试验测定抗毒素水平。
接种疫苗前,100名受试者中有30人对白喉有保护作用(抗毒素水平>0.1 IU/ml),24人有“基础免疫力”(0.01至<0.1 IU/ml),46人没有可测量的保护作用(<0.01 IU/ml)。首次加强免疫后,100人中有7人未达到保护阈值,他们均为女性。接种疫苗前后抗毒素水平的主要决定因素是自上次接种以来的间隔时间。此外,女性接种疫苗前后的水平明显低于男性。但在第二次和第三次加强免疫后,这7名女性的抗毒素水平升至保护阈值以上,而整个群体的几何平均值下降,尽管进行了进一步的加强免疫。接种疫苗前为0.015 IU/ml,首次加强免疫后为1.156 IU/ml,第二次后为0.924 IU/ml,第三次后为0.952 IU/ml。
那些上次接种白喉疫苗超过20年的成年人应间隔8周以上进行两次加强注射,以便达到尽可能高且最持久的抗毒素水平。特别是女性应至少进行两次加强注射,因为她们的抗毒素反应往往比男性小。